Key Highlights

  • Shares rose 1.65% in today's session to around $7.09 on new long-term psoriasis trial data.
  • More than 80% of patients maintained clear or almost-clear scalp skin after 48 weeks of treatment.
  • A 54% PASI 100 complete skin clearance rate was reported at week 48, among the highest publicly reported for an oral psoriasis therapy.
  • The company remains on track to submit its FDA application in the fourth quarter of 2026.

ONWARD Program Data Shows Durable Results

Alumis (NASDAQ:ALMS) shares rose in today's session after the company presented new data from its Phase 3 ONWARD clinical program for envudeucitinib, an oral pill being developed for moderate to severe plaque psoriasis. The results were presented at the Fall Clinical Dermatology Conference 2026.

Alumis is a late-stage biopharmaceutical company developing oral treatments that target immune-mediated diseases, with envudeucitinib built around precision inhibition of an enzyme called TYK2, which plays a role in several inflammatory conditions.

Scalp Clearance and Itch Relief Stand Out

More than 80% of patients in the long-term extension study maintained clear or almost-clear scalp skin at 48 weeks, addressing an area of the body that is often difficult to treat. Nearly 80% of patients also sustained meaningful itch relief through the same period.

The program reported a 54% complete skin clearance rate at week 48, among the highest publicly reported figures for an investigational oral psoriasis therapy. Patients who switched from placebo or an older comparator drug also caught up quickly, reaching responses comparable to those on continuous treatment.

A Growing Pipeline Beyond Psoriasis

Alumis carries a market Capitalization of roughly $875 million. Beyond envudeucitinib, the company is developing A-005, a separate TYK2 inhibitor aimed at neuroinflammatory and neurodegenerative conditions such as Parkinson's disease, giving the pipeline potential reach beyond its lead psoriasis indication.

Outlook: Fourth-Quarter NDA Filing Is the Next Major Step

With the company reaffirming plans to file for FDA approval in the fourth quarter of 2026, investors are likely to watch closely for the formal submission and any feedback from regulators in the months that follow. Continued durability in long-term data could support the case for envudeucitinib as a leading oral option in the category.